Precision Biologics along with our collaborators at the National Cancer Institute present research data using...
Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...
Dr Massimo Fantini, Senior Scientist is Presenting the following Talk entitled: "Mechanisms of action of...
Ariel Cahill Hollinshead Hyun, PhD, a pioneering cancer researcher whose work contributed to the foundation...
NEO-201 is an IgG1 mAb targeting variants of CEACAM5/6 that demonstrates tumor sensitivity and specificity....
This is a first-in-human phase 1 study to determine the maximum tolerated dose (MTD) and...
The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of...
Most monoclonal antibody cancer therapies are developed for known targets and are commercially approved for...
